Press Release: Basilea: ERADICATE phase 3 study -2-

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations

Basilea Pharmaceutica International Ltd, Allschwil

Hegenheimermattweg 167b

4123 Allschwil

Switzerland

Phone +41 61 606 1102

E-mail media_relations@basilea.com

investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

References

1. ERADICATE: ClinicalTrials.gov identifier NCT03138733K. Hamed,

M. Engelhardt, M. E. Jones et al. Ceftobiprole versus daptomycin in

Staphylococcus aureus bacteremia: a novel protocol for a double-blind,

Phase III trial. Future Microbiology. 2020 (1), 35-48

2. Summary of Product Characteristics (SmPC)

Zevtera: https://www.medicines.org.uk/emc/product/9164/smpc [Accessed:

October 23, 2022]

3. TARGET: ClinicalTrials.gov identifier NCT03137173J. S. Overcash, C. Kim,

R. Keech R et al. Ceftobiprole Compared With Vancomycin Plus Aztreonam in

the Treatment of Acute Bacterial Skin and Skin Structure Infections:

Results of a Phase 3, Randomized, Double-blind Trial (TARGET). Clinical

Infectious Diseases 2021 (73), e1507-e1517

4. A. G. Jensen, C. H. Wachmann, F. Espersen et al. Treatment and outcome of

Staphylococcus aureus bacteremia: a prospective study of 278 cases.

Archives of Internal Medicine 2002 (162), 25-32

5. J.-L. Wang, S.-Y. Chen, J.-T. Wang et al. Comparison of both clinical

features and mortality risk associated with bacteremia due to

community-acquired methicillin-resistant Staphylococcus aureus and

methicillin-susceptible S. aureus. Clinical Infectious Diseases 2008 (46),

799-806

6. S. I. Blot, K. H. Vandewoude, E. A. Hoste et al. Outcome and attributable

mortality in critically ill patients with bacteremia involving

methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Archives of Internal Medicine 2002 (162), 2229-2235

7. S. E. Cosgrove, G. Sakoulas, E. N. Perencevich et al. Comparison of

mortality associated with methicillin-resistant and

methicillin-susceptible Staphylococcus aureus bacteremia: a

meta-analysis. Clinical Infectious Diseases 2003 (36), 53-59

Attachment

-- Press release (PDF)

https://ml-eu.globenewswire.com/Resource/Download/b6bf4996-c897-4111-a9f3-9cbe07128f65

(END) Dow Jones Newswires

October 24, 2022 01:15 ET (05:15 GMT)